

## BioSenic provides further information on its restructuring plan

Mont-Saint-Guibert, Belgium, 12 April 2024, 12:00 CET – [BioSenic](#) (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, as part of the global restructuring plan announced on 11 April 2024, provides information on (i) the Company's current debt position and the potential impact of the plan on this position and (ii) links to the Company's website to consult the conversion terms and conditions offered to holders of convertible bonds (excluding Global Tech Opportunities 15) as part of the plan.

The impact that the global restructuring plan could have on BioSenic's debt position is as follows:

	Due	Paid within 5 years	31/12/2030 + 24 months
Extraordinary lease	€ 61.211,77	€ 61.211,77	
Ordinary	€ 2.750.655,64	€ 137.532,78	
Strategic	€ 223.869,65	€ 201.482,69	
Accessories employee	€ 8.736,45	€ 8.649,09	
Interco	€ 8.736,45	€ 436,82	
Very useful	€ 344.209,67	€ 172.104,84	
Shareholder	€ 124.912,50	0	
Non-convertible bonds	€ 4.121.800,00		€ 4.121.800,00
Convertible bonds	€ 2.000.000,00		€ 2.000.000,00
Loan	€ 1.500.000,00		€ 1.500.000,00
Bullet	€ 8.487.200,00		€ 8.487.200,00
<b>Sub-total allocated</b>	<b>€ 19.631.332,13</b>	<b>€ 581.417,99</b>	<b>€ 16.109.000,00</b>
Unallocated	Converted	€ 2.400.000,00	
<b>Total</b>	<b>€ 22.031.332,13</b>	<b>€ 581.417,99</b>	<b>€ 16.109.000,00</b>

It should be noted, however, that this table only shows the potential impact of the plan if it were to be accepted as it stands and does not take into account any new debt that the Company may incur in the future. This is also a non-consolidated view of the Company, as the debt of the subsidiary Medsenic is not taken into account.

BioSenic has also posted a summary of the conversion terms offered to holders of convertible bonds (excluding Global Tech Opportunities 15) under the plan on the "investors" section of its website and accessible via the following link: [https://biosenic.com/sites/default/files/2024-04/BioSenic\\_summary%20bonds%20refinancing\\_20240411.pdf](https://biosenic.com/sites/default/files/2024-04/BioSenic_summary%20bonds%20refinancing_20240411.pdf)

### About BioSenic

BioSenic is a leading biotech company specializing in the development of clinical assets issued from its Medsenic's arsenic trioxide (ATO) platform. Key target indications for the autoimmune platform include graft-versus-host-disease (GvHD), systemic lupus erythematosus (SLE), and now systemic sclerosis (SSc).

Following the merger in October 2022, BioSenic combined the strategic positionings and strengths of Medsenic and Bone Therapeutics. The merger specifically enables Medsenic/Biosenic to develop an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/oral ATO (OATO).

BioSenic is based in the Louvain-la-Neuve Science Park in Mont-Saint-Guibert, Belgium. Further information is available at <http://www.biosenic.com>.

## About the main Medsenic/BioSenic technology platform

The **ATO platform** provides derived active products with immunomodulatory properties and fundamental effects on the activated cells of the immune system. One direct application is its use in onco-immunology to treat GvHD (Graft-versus-Host Disease) in its chronic, established stage. cGvHD is one of the most common and clinically significant complications affecting long-term survival of allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Medsenic has been successful in a phase 2 trial with its intravenous formulation, **Arscimed®**, which has orphan drug designation status by FDA and EMA. The company is heading towards an international phase 3 confirmatory study, with its new, IP-protected, OATO formulation. Another selected target is moderate-to-severe forms of systemic lupus erythematosus (SLE), using the same oral formulation. ATO has shown good safety and significant clinical efficacy on several affected organs (skin, mucosae, and the gastrointestinal tract). Systemic sclerosis is now full part of the clinical pipeline of Medsenic/BioSenic. This serious chronic disease badly affects skin, lungs, or vascularization, and has no current effective treatment. Preclinical studies on pertinent animal models are positive, giving good grounds to launch a phase 2 clinical protocol, using new immunomodulatory formulations of APIs recognized to be active on the immune system.

The company is currently focusing its present R&D and clinical activities on a selective, accelerated development of its autoimmune platform.

Note: The allogeneic cell therapy platform-originating from the previous listed company Bone Therapeutics company, may be of renewed interest by using isolated and purified differentiated bone marrow Mesenchymal Stromal Cells (MSCs) as a starting material for further isolation of passive or active biological subcellular elements. Indeed, these cells may provide new subcellular vesicles potentially able to deliver a unique and proprietary approach to organ repair. BioSenic is now involved in determining new patentable approaches in this complex area of cell therapy.

## For further information, please contact:

### BioSenic SA

François Rieger, PhD, CEO

Tel: +33 (0)671 73 31 59

investorrelations@biosenic.com

International Media Enquiries:

### IB Communications

Michelle Boxall

Tel: +44 (0)20 8943 4685

michelle@ibcomms.agency

French Investor Enquiries:

### Seitosei• Actifin

Ghislaine Gasparetto

Tel: +33 (0)1 56 88 11 22

ghislaine.gasparetto@seitosei-actifin.com

Michael Scholze

michael.scholze@seitosei-actifin.com

---

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the company or, as appropriate, the company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

---